Extend your brand profile by curating daily news.

Ace Therapeutics Preclinical Analgesic Drug Development FAQ

Ace Therapeutics announces comprehensive preclinical analgesic drug development services with a full-spectrum pain research platform, covering target discovery to safety assessment for pharmaceutical and biotech customers worldwide.
Ace Therapeutics Preclinical Analgesic Drug Development FAQ

Ace Therapeutics provides end-to-end preclinical analgesic drug development services, including target discovery, mechanism verification, pharmacological validation, safety assessment, in vivo pain models, in vitro neuropathic pain models, and drug discovery for small molecules, biologics, cell therapies, and gene therapies.

They offer validated animal models for migraine (via trigeminal ganglion electrical stimulation or nitroglycerin induction) and neuropathic pain (spinal nerve ligation, chronic constriction injury, diabetic neuropathic pain models), covering nearly all mainstream pain classifications.

They use mechanical, thermal, chemical, cold, and electrical stimulation tests, including Von Frey Filament, Hot Plate, and Formalin tests.

Yes, they provide in vitro neuropathic pain model development using dorsal root ganglion (DRG) cells, iPSC-derived sensory neurons, and co-culture systems to explore cellular pain mechanisms.

They support small-molecule analgesics, biologics (antibodies, recombinant proteins, peptides), cell therapies, and gene therapy candidates.

The pipeline includes target validation, in vitro screening, in vivo pharmacology, pharmacokinetics, safety pharmacology, preclinical formulation development, biomarker discovery, PK/PD modeling, toxicity assessment, and formulation optimization.

Yes, they can design customized pain models and testing assays based on unique drug mechanisms and research objectives.

Ace Therapeutics is a preclinical contract research organization specializing in analgesic drug development, offering one-stop preclinical research services.

NewsRamp Editorial Team

NewsRamp Editorial Team

@newsramp

NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.